Three Meningioma Cases With a BAP1 Gene Change
Original title: Clinical and Molecular Features of BAP1-Mutated Meningiomas: Case Series.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report on three patients that were watched over time, not a test of a new treatment.
The short version
Doctors describe three people whose meningioma had a change in a gene called BAP1, and each person did very differently.
What was studied. Doctors reported on three people with meningioma. Each tumor had a change in a gene called BAP1. The report looked at the type of gene change, the tumor grade, and how each person did over time.
What they found. A 44-year-old woman had a WHO grade 1 tumor, but it came back quickly and needed more surgery, radiation, and drug treatment. A 22-year-old man had a WHO grade 3 tumor and a family history of meningioma, and his tumor had not grown back 24 months after surgery and radiation. A 57-year-old man had a WHO grade 2 tumor and was doing well 26 months after surgery with no extra treatment.
What this means, and what it doesn't
What it could mean: The type of BAP1 change may matter, not just the tumor grade. Some tumors that look low grade under the microscope may still come back fast. The authors say gene testing could help doctors judge risk along with the usual grading.
What it doesn't mean: This is not a treatment, and it is not a cure. It is a report on three people only. Three people cannot tell us what will happen to everyone else. No drug was tested here, and nothing was compared to standard care. BAP1 testing is not yet part of the official tumor grading system. Talk to your own care team about what fits your case.
Source: PubMed, July 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.